Q2 2024 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2024-08-14 · accession 0001213900-24-068546
$1.08B
Reported value
42
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $298.5M | 27.6% | 7,316,851 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $115.4M | 10.7% | 27,225,292 | Common | SOLE |
| 413197104 | HRMY | Harmony Biosciences Holdings Inc | $78.6M | 7.26% | 2,606,247 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $76.3M | 7.05% | 11,800,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $57.7M | 5.33% | 1,635,136 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $55.8M | 5.16% | 3,972,099 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $51.3M | 4.74% | 3,549,758 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $42.1M | 3.89% | 6,182,992 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $25.4M | 2.35% | 4,220,048 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $21.8M | 2.02% | 1,678,207 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $21.2M | 1.96% | 2,329,027 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $21.0M | 1.94% | 1,105,454 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $20.3M | 1.87% | 1,873,704 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $18.9M | 1.75% | 2,244,941 | Common | SOLE |
| 29479A108 | ERAS | Erasca Inc | $15.9M | 1.47% | 6,756,756 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $15.4M | 1.42% | 565,550 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $14.0M | 1.29% | 1,666,746 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $12.0M | 1.11% | 2,797,704 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $10.0M | 0.92% | 610,500 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $9.8M | 0.90% | 1,650,440 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $9.7M | 0.90% | 1,608,000 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $9.2M | 0.85% | 531,198 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $9.0M | 0.83% | 1,269,676 | Common | SOLE |
| 75915K309 | RGLS | Regulus Therapeutics Inc | $8.9M | 0.82% | 5,000,000 | Common | SOLE |
| 00289Y206 | ABEO | Abeona Therapeutics, Inc. | $7.8M | 0.72% | 1,842,751 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $7.6M | 0.70% | 591,882 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holdings | $7.5M | 0.70% | 166,794 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $7.2M | 0.67% | 6,173,439 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $6.4M | 0.59% | 624,339 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc. | $6.4M | 0.59% | 678,705 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $4.6M | 0.42% | 1,538,461 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $3.6M | 0.33% | 3,556,023 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos Inc | $3.0M | 0.28% | 2,988,000 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Therapeutics Inc | $2.6M | 0.24% | 3,521,291 | Common | SOLE |
| 90466Y103 | — | Unicycive Therapeutics | $1.7M | 0.16% | 3,470,152 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics Inc | $1.2M | 0.11% | 3,547,030 | Common | SOLE |
| 192005106 | CDXS | Codexis, Inc | $1.2M | 0.11% | 388,144 | Common | SOLE |
| 23306J200 | — | DBV Technologies SA | $1.1M | 0.10% | 1,354,437 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $833,333 | 0.08% | 833,333 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience Inc | $743,975 | 0.07% | 509,572 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $369,034 | 0.03% | 20,559 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $45,489 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.